Etest cannot be recommended for in vitro susceptibility testing of mucorales

Rita Caramalho; Elisabeth Maurer; Ulrike Binder; Ricardo Araújo; Somayeh Dolatabadi; Cornelia Lass-Flörl; Michaela Lackner

doi:10.1128/AAC.00004-15

Etest cannot be recommended for in vitro susceptibility testing of mucorales

Antimicrob Agents Chemother. 2015;59(6):3663-5. doi: 10.1128/AAC.00004-15. Epub 2015 Apr 6.

Authors

Rita Caramalho¹, Elisabeth Maurer¹, Ulrike Binder¹, Ricardo Araújo², Somayeh Dolatabadi³, Cornelia Lass-Flörl¹, Michaela Lackner⁴

Affiliations

¹ Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
² Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal Faculty of Sciences, University of Porto, Porto, Portugal.
³ CBS Fungal Biodiversity Centre, Institute of the Royal Netherlands Academy of Arts and Sciences (KNAW), Utrecht, The Netherlands Institute for Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands.
⁴ Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria [email protected].

Abstract

Amphotericin B and posaconazole susceptibility patterns were determined for the most prevalent Mucorales, following EUCAST (European Committee on Antimicrobial Susceptibility Testing) broth microdilution guidelines. In parallel, Etest was performed and evaluated against EUCAST. The overall agreement of MICs gained with Etest and EUCAST was 75.1%; therefore, Etest cannot be recommended for antifungal susceptibility testing of Mucorales. Amphotericin B was the most active drug against Mucorales species in vitro, while the activities of posaconazole were more restricted.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Amphotericin B / pharmacology
Antifungal Agents / pharmacology
Microbial Sensitivity Tests / methods*
Microbial Sensitivity Tests / standards*
Mucorales / drug effects*

Substances

Antifungal Agents
Amphotericin B